Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Sitryx Therapeutics
First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026
May 21, 2026
Sitryx nominates novel, oral GLS1 inhibitor for clinical development in moderate to severe asthma
May 20, 2026
Sitryx to participate in upcoming April investor conferences
May 19, 2026
Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity
February 3, 2026